[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:nodular-lymphocyte-predominant-hodgkin-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":21,"states":22},"Nodular Lymphocyte-Predominant Hodgkin Lymphoma",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05886036","Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial",[11],"Phase 2","RECRUITING","2026-08-26T02:18:39.640967Z","2026-07-30T01:46:14.465297Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06098430","Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)",[],"2026-08-26T02:19:21.761002Z","2026-05-13T02:55:06.415525Z",[],[]]